Clinical Trial Update: Elranatamab in R/R Multiple Myeloma [Phase 2]

View source ↗

Summary

Elranatamab is being studied in a Phase 2 trial for patients with refractory or relapsed multiple myeloma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Status: RECRUITING